Drug Trial Radar · NCT01681992
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Last checked: Nov 19, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,538
Actual
Start
Oct 10, 2012
Primary completion
Feb 3, 2015
Study completion Aug 18, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Conditions
- Measles
- Mumps
- Rubella
- Measles-Mumps-Rubella Vaccine
Interventions
PriorixBiological
Subjects receive one dose of either minimum (Inv\_MMR\_Min) or medium (Inv\_MMR\_Med) potency lot at Day 0 and a dose of separate potency lot (Inv\_MMR\_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
M-M-R IIBiological
Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
VarivaxBiological
Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
HavrixBiological
Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Prevnar 13Biological
US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA])Time frame: At Day 42
- Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA)Time frame: At Day 42
- Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by Plaque Reduction Neutralization Test [PRNT])Time frame: At Day 42
- Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA)Time frame: At Day 42
- Anti-measles Virus Antibody Concentrations (by ELISA)Time frame: At Day 42
- Anti-mumps Virus Antibody Concentrations (by ELISA)Time frame: At Day 42
- Anti-mumps Virus Antibody Concentrations (by PRNT)Time frame: At Day 42
- Anti-rubella Virus Antibody Concentrations (by ELISA)Time frame: At Day 42
Locations
81 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
West Covina, California
GSK Investigational Site
Altamonte Springs, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
Naples, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Muncie, Indiana
GSK Investigational Site
New Albany, Indiana
GSK Investigational Site
West Des Moines, Iowa
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Annapolis, Maryland
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Frederick, Maryland
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Clyde, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Toledo, Ohio
GSK Investigational Site
Youngstown, Ohio
GSK Investigational Site
Gresham, Oregon
GSK Investigational Site
Johnstown, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Layton, Utah
GSK Investigational Site
Springville, Utah
GSK Investigational Site
St. George, Utah
GSK Investigational Site
Midlothian, Virginia
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Ellensburg, Washington
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.